A clinical view on BET inhibition in targeting residual risk in CVD and diabetes
Video navigation menu
- Available interventions that reduce CVD 0:47
- The role of BET inhibition in the development of CVD 3:10
- Observed reduction in CVD events with apabetalone 4:38
- Aim and study design of BETonMACE 7:36
This lecture was part of a CME accredited symposium: "LDL-c: Done Deal, Next Epigenetics?" during ESC 2018 in Munich, Germany.
Kausik Ray, MD, is a cardiologist, and Professor of Public Health/Honorary Consultant Cardiologist at Imperial College London, United Kingdom.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.